Bonum Health(TM), LLC (a TRxADE HEALTH Company) Reaffirms its Commitment to Independent Pharmacies and Group Purchasing Organizations (GPOs) with its Novel Telemedicine Services Model

TAMPA, FL / ACCESSWIRE / December 6, 2022 / TRxADE HEALTH, INC. (NASDAQ:MEDS)("TRxADE" or the "Company") an integrated drug procurement, delivery, and healthcare platform, today announced that Bonum Health, a Digital Healthcare business subsidiary, has signed a preferred telemedicine services agreement with an independent group purchasing organization (GPO) which will provide deep discounts to access Bonum Health's service platform for 100+ pharmacies and their patient's in the northeastern part of the United States.

The Company, which offers nationwide telemedicine services in all 50 states for humans and select states for pets, has grown its presence with independent pharmacies by promoting telemedicine services to its patient base. Dr. Shafaat Pirani, PharmD, BCGP, Chief Clinical and Compliance Officer for TRxADE states, "We have seen an increase in interest among the independent pharmacy community who are looking to diversify their service offerings to patients by providing affordable access to telehealth solutions for the growing uninsured and under-insured patient population. In most states, pharmacists are not recognized as Providers with prescriptive authority, and must therefore submit medication recommendations to the prescriber, which often leads to delays in therapy which may lead to adverse outcomes for patients. The ability to connect a patient with a telemedicine provider using our mobile application, for a simple medication refill or to prescribe an acute course of antibiotics or steroids for an infection, is the type of convenience we believe patients are seeking in today's digital environment."

Dr. Pirani went on to further discuss that, "We have seen that independent pharmacies that do not provide in-house clinical services are losing patients to the enterprise pharmacy chains, like CVS Health's Health Hub Model or via Walgreen's Village MD Clinic Partnership, where patients can walk in and quickly see a provider in person. We are working to provide a solution to this problem for the nation's independent pharmacies, by strategically working with and recruiting GPOs to promote Bonum Health's service offering, while also providing deeper discounts to patients based on market share. Our strategy is focused on garnering strategic business-to-business (B2B) opportunities like this, and we believe we have several opportunities in the immediate pipeline."

Suren Ajjarapu, Chairman and Chief Executive Officer of TRxADE added, "We are pleased to see such a positive response from the independent pharmacy community. Our mission at TRxADE has been to empower the independent pharmacy market by providing cost savings on pharmaceutical products, and we see an opportunity to help boost foot traffic and prescriptions to our network of pharmacies." Mr. Ajjarapu added, "We have operated with success in the business-to-business (B2B) markets and we believe that partnering with independent GPOs and buying groups will continue to enhance our position and provide value to our eco-system of pharmacies."

About TRxADE HEALTH, INC.

TRxADE HEALTH (NASDAQ:MEDS) is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey, and patient engagement in the U.S. The Company operates the TRxADE drug procurement marketplace serving a total of 14,100+ members nationwide, fostering price transparency, and under the Bonum Health brand, offering patient-centric telehealth services and tele vet services. For information on TRxADE, please visit the Company's IR website at investors.trxadehealth.com.

Forward-Looking Statements

This press release may contain forward-looking statements, including information about management's view of TRxADE's future expectations, plans, and prospects, within the meaning of the federal securities laws, including the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. In particular, when used in the preceding discussion, the words "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue," "likely," "will," "would" and variations of these terms and similar expressions, or the negative of these terms or similar expressions are intended to identify forward-looking statements. Any statements made in this news release other than those of historical fact, about an action, event, or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of TRxADE, its divisions, and concepts to be materially different from those expressed or implied in such statements. These risks include risks relating to agreements with third parties; including Wakefern Food Corp., Coborn's, Galt Pharmaceuticals, and others; our ability to raise funding in the future, as and if needed, and the availability and terms of such funding, including potential dilution caused thereby; TRxADE's ability to continue as a going concern; the planned benefits, expected users of and projected revenues of our venture with Exchange Health and other third parties; amounts we owe and may owe to Exchange Health in connection with the arrangement with Exchange Health; security interests under certain of our credit arrangements; the fact that we are exploring strategic alternatives for our B2C subsidiaries, including Bonum Health, Inc.; our ability to maintain the listing of our common stock on the Nasdaq Capital Market, including our current non-compliance with the continued listing standards of the Nasdaq Capital Market; risks associated with TRxADE's operations not being profitable; the commercial viability of new business lines, applications, products and technologies, and the costs of such items; the adoption of the Company's product offerings; claims relating to alleged violations of intellectual property rights of others; our ability to monetize our technological solutions; technical problems with our websites, apps, and products; risks relating to implementing our acquisition strategies; challenges to the pharmaceutical supply chain posted by the COVID-19 pandemic and related matters; our ability to manage our growth; negative effects on our operations associated with the opioid pain medication health crisis; regulatory and licensing requirement risks; risks related to changes in the U.S. healthcare environment; the status of our information systems, facilities and distribution networks; risks associated with the operations of our more established competitors; regulatory changes; new competitors which may have more resources than we do; increases in direct to consumer sales of drugs; healthcare fraud; COVID-19, governmental responses thereto, economic downturns and increased inflation and possible recessions caused thereby; changes in laws or regulations relating to our operations; privacy laws; system errors; dependence on current management; our growth strategy; dilution which may be caused by future offerings; increased inflation and interest rates, including the increased costs of raising funding as a result thereof; supply chain issues caused by among other things, recessions and global conflicts; and others that are included from time to time in filings made by TRxADE with the Securities and Exchange Commission, including, but not limited to, in the "Cautionary Note Regarding Forward-Looking Statements" and "Risk Factors" sections in its Form 10-Ks and Form 10-Qs and in its Form 8-Ks, which it has filed, and files from time to time, with the U.S. Securities and Exchange Commission (SEC), and more particularly in the Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 and our Annual Report on Form 10-K for the year ended December 31, 2021. These reports are available at www.sec.gov. Other unknown or unpredictable factors also could have material adverse effects on TRxADE's future results and/or could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements. The forward-looking statements included in this press release are made only as of the date hereof. TRxADE cannot guarantee future results, levels of activity, performance, or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions, or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

Media Contact/Investor Relations:

IR@trxade.com

Investors.trxadegroup.com

(800) 261-0281

SOURCE: TRxADE HEALTH, INC.